MedTrace Logo

Gremlin-1 and Wagner Classification: Potential Biomarker for Amputation in Diabetic Foot Patients

NCT06753604 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 85

Last updated 2024-12-31

No results posted yet for this study

Summary

The aim of the approach to diabetic foot patients is to heal the wound, mobilize the patient, increase the quality of life, and reduce DA-related amputations as much as possible. For this purpose, early diagnosis and early intervention with multidisciplinary treatment methods are important. There is no marker used to determine the prognosis, predict the progression to amputation, and take precautions for diabetic foot.

Based on this need, investigators planned to examine the gremlin-1 level in patients with diabetic foot wounds by grouping them according to the severity of the disease (according to the Wagner classification). There is no previous study examining the relationship between gremlin-1, which has been shown to play a role in inflammation, fibrosis, and angiogenesis, and diabetic foot.

In this study, investigators aimed to show the relationship between gremlin-1 in diabetic foot and Wagner classification and its usability as a biomarker in progression to amputation. Being the first study to be conducted on this subject in the literature increases the importance of the project.

Conditions

  • Diabetes Mellitus
  • Diabetic Foot Disease
  • Diabetic Foot Ulcer
  • Diabetic Neuropathy
  • Peripheral Arterial Disease

Sponsors & Collaborators

  • Ege University

    collaborator OTHER

  • Seyma Acik

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-20
Primary Completion
2020-10-20
Completion
2021-02-27

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06753604 on ClinicalTrials.gov